Abbott Labs (ABT) Stock Price Target Raised at Barclays

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016.

Stated diluted EPS from continuing operations under GAAP was $0.40 in the second quarter. The stock has a 50-day moving average price of $39.67 and a 200-day moving average price of $39.91.

Shares of the company advanced 3.11 percent in Wednesday’s pre-market trading. The stock holds the market capitalization of $62.23B along with 1.47B outstanding shares.

Abbott’s full-year 2016 EPS for continuing operations under GAAP is projected to be $1.26 to $1.36.

Commenting on the results, the company’s chairman and CEO, Miles White, said, “It was a good quarter”. Abbott Laboratories has a 52-week low of $36.00 and a 52-week high of $51.47.

Abbott Laboratories (NYSE:ABT) as of current trade, has shown weekly upbeat performance of 1.62%.

In July, Abbott received U.S. FDA approval for Absorb, the only fully dissolving heart stent, as well as U.S. FDA approval for TECNIS Symfony intraocular lenses for the treatment of cataracts, the first and only extended depth of focus lenses for people with cataracts. The transaction will create a premier medical device leader with a highly competitive portfolio that will include an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

The Company gained 0.82% and finished at $43. Eight research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company.

Learn how you could trade stocks with 91% to 100% success rate by using this revolutionary indicator that predicts when certain stocks are on the move.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) after beginning at $2.45, closed at $2.66 by building up +8.13% in recent trading session. The daily volume was measured at 10.34 million shares. Stock’s minimum price target estimates has been figured out at $45.00 while the maximum price target forecast is established at $50.00. This represents a $1.04 dividend on an annualized basis and a dividend yield of 2.42%.

In the liquidity ratio analysis; Eleven Biotherapeutics, Inc.’s (EBIO) debt to equity ratio was 0.00 while current ratio was 6.00.

Other institutional investors also recently bought and sold shares of the company.